Social Sentiment Ticker Powered by AI

DOW/USDDow Jones Industrial Average/USD
38,459.08
0.00
neutral
SPX/USDStandard & Poor’s 500/USD
5,199.06
0.00
neutral
NDX/USDNASDAQ-100/USD
18,307.98
0.00
neutral
BTC/USDBitcoin – United States Dollar/USD
70,985.58
+939.18(1.34%)
bullish
ETH/USDEthereum – United States Dollar/USD
3,535.99
+32.93(0.94%)
bullish
XRP/USDRipple – United States Dollar/USD
0.61
+0.00(0.04%)
bullish
DOGE/USDDogecoin – United States Dollar/USD
0.20
+0.01(3.18%)
bullish
AAPL/USDApple Inc./USD
174.92
-0.12(0.07%)
bearish
GOOGL/USDAlphabet Inc. Class A Common Stock/USD
158.51
-0.90(0.56%)
bearish
TSLA/USDTesla, Inc. Common Stock/USD
173.43
-1.17(0.67%)
bearish
META/USDMeta Platforms, Inc. Class A Common Stock/USD
520.02
-3.14(0.60%)
bearish
NVDA/USDNvidia Corp/USD
903.24
-2.92(0.32%)
bearish
AMD/USDAdvanced Micro Devices/USD
167.37
-3.13(1.84%)
bearish
COIN/USDCoinbase Global, Inc. Class A Common Stock/USD
262.47
-0.54(0.21%)
bearish
NFLX/USDNetFlix Inc/USD
632.53
+3.75(0.60%)
bullish

Social Sentiment Ticker Powered by AI

DOW/USDDow Jones Industrial Average/USD
38,459.08
0.00
neutral
SPX/USDStandard & Poor’s 500/USD
5,199.06
0.00
neutral
NDX/USDNASDAQ-100/USD
18,307.98
0.00
neutral
BTC/USDBitcoin – United States Dollar/USD
70,985.58
+939.18(1.34%)
bullish
ETH/USDEthereum – United States Dollar/USD
3,535.99
+32.93(0.94%)
bullish
XRP/USDRipple – United States Dollar/USD
0.61
+0.00(0.04%)
bullish
DOGE/USDDogecoin – United States Dollar/USD
0.20
+0.01(3.18%)
bullish
AAPL/USDApple Inc./USD
174.92
-0.12(0.07%)
bearish
GOOGL/USDAlphabet Inc. Class A Common Stock/USD
158.51
-0.90(0.56%)
bearish
TSLA/USDTesla, Inc. Common Stock/USD
173.43
-1.17(0.67%)
bearish
META/USDMeta Platforms, Inc. Class A Common Stock/USD
520.02
-3.14(0.60%)
bearish
NVDA/USDNvidia Corp/USD
903.24
-2.92(0.32%)
bearish
AMD/USDAdvanced Micro Devices/USD
167.37
-3.13(1.84%)
bearish
COIN/USDCoinbase Global, Inc. Class A Common Stock/USD
262.47
-0.54(0.21%)
bearish
NFLX/USDNetFlix Inc/USD
632.53
+3.75(0.60%)
bullish

Download App

For a Limited Time Get 1 Month Free of TradeZing+

For a Limited Time Get 1 Month Free of TradeZing+

Learn More
Back

Live Audio Room

No related audio room.

Related Events

No related events.


Latest Feed

0

April 12, 2024

19 mins ago

# of Events: 0

Jim Cramer Says He ‘Would Sell’ This Tesla Chinese Rival After Stock Lost Over 47% In 2024

Jim Cramer offered a stark recommendation for shareholders of the electric vehicle company NIO Inc. (NYSE:NIO). What Happened: Cramer recommended selling shares of NIO during CNBC’s Lightning Round on Thursday. “I would sell,” he said. Tesla Inc‘s Chinese rival stock has lost 47% of its value since the beginning of this year. The stock closed near its 52-week low of $4.36 on Thursday, according to data from Benzinga Pro. See Also: Trump Media’s Stock Takes A Dramatic Nosedive, Erasing All Gains Since Public Debut Why It Matters: NIO’s market performance has been under scrutiny, with an analyst report from early March highlighting a challenging outlook for the company in 2024. The report flagged concerns over NIO’s shrinking market share, as the electric vehicle deliveries in China continue to decline. Adding to the company’s challenges, …Full story available on Benzinga.com

NIO

0

164985

News

0

April 12, 2024

27 mins ago

# of Events: 0

Evome Strengthens Major Creditor Relationship After the Sale of the Simbex Unit to Riddell, LOI Related to Simbex Acquisition Debt is Cancelled

NEW YORK, April 12, 2024 (GLOBE NEWSWIRE) — Evome Medical Technologies Inc (the “Company” or “Evome”) highlighted the strengthening credit relationship with Pathward, N.A. (“Pathward”), the Company’s senior lender. As the Company works to sell non-core business units to reduce acquisition debt in an effort to improve operational profitability, Pathward provides working capital to fuel revenue growth of the Company’s new Biodex products. Pathward has featured the strong and growing relationship with Evome as an example of its willingness to fund growth companies:

EVMT

0

164988

News

0

April 12, 2024

27 mins ago

# of Events: 0

Invivyd Announces CEO Transition

Jeremy Gowler appointed Interim CEO Jeremy Gowler appointed Interim CEO

IVVD

0

164987

News


0

November 21, 2023
5 months ago

Can Weight-Loss Drug Ozempic Tip The Scales For Tema’s New Healthcare ETF?

Tema, the exchange-traded fund platform, has launched a healthcare ETF focused on companies that research and treat cardiovascular disease and conditions associated with obesity and diabetes, including Novo Nordisk, maker of the blockbuster diet drug Ozempic. The Tema Cardiovascular and Metabolics ETF (NASDAQ:HRST) launches on the NASDAQ exchange on Tuesday and will look to cash in on the massive popularity of a new breed of drugs called semaglutides, which include Novo Norkdisk‘s (NYSE:NVO) Ozempic and Wegovy and Eli Lilly‘s (NYSE:LLY) Mounjaro. “Cardiovascular and metabolic diseases are closely intertwined, combining a larger, well-established area of healthcare with a burgeoning new biopharma sector: obesity,” said Maurits Pot, co-founder and CEO of TEMA. “This area has recently announced and launched several breakthrough therapies underscoring the pace of innovation that we believe will transform patient lives and outcomes.” Also Read: …Full story available on Benzinga.com

Continue Reading

Feed Topics

News

Feed Tags

LLY

NVO

PFE

Subscribe

Notify of


0 Comments


Inline Feedbacks
View all comments

Copied